ProKidney Corp.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ProKidney Corp.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-4.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 56% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-112.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 85% of Healthcare companies in United States.
Cash Cushion Ratio
+47%Cash, after subtracting all debt, equals 47% of its market value (net cash).
Higher than 77% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
ProKidney Corp. made a loss over the last year. ProKidney Corp. owes $0.11 for every $1 it owns. ProKidney Corp. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossProKidney Corp. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.65ProKidney Corp.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$571 MThe total market value of all of ProKidney Corp.'s shares at today's price (share price × number of shares), larger than 56% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeProKidney Corp.'s net worth is negative ($884 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-59.0%ProKidney Corp. lost 59.0% of its shareholders' money over the last year, lower than 56% of Healthcare companies in United States.
Owes vs Owns
0.11×ProKidney Corp. owes $0.11 for every $1 it owns (low), lower than 86% of Healthcare companies in United States.
Dividend yield
NoneProKidney Corp. does not currently pay a dividend.
Revenue growth
+1075%Revenue rose 1075% in the year to Dec 2025.
Profit growth
LossProKidney Corp. made a loss in each of the last two years.
Profit margin
-7725.2%ProKidney Corp. lost $7725 for every $100 of revenue.
Interest cover
Not coveredProKidney Corp.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashProKidney Corp. held $266 M more cash than debt (net cash) at Dec 2025.
Questions
What is ProKidney Corp.'s return on equity?
ProKidney Corp. lost 59.0% of its shareholders' money over the last year, lower than 56% of Healthcare companies in United States.
How much does ProKidney Corp. owe compared with what it owns?
ProKidney Corp. owes $0.11 for every $1 it owns (low), lower than 86% of Healthcare companies in United States.
Does ProKidney Corp. pay a dividend?
No. ProKidney Corp. does not currently pay a dividend.
Is ProKidney Corp.'s revenue growing?
Revenue rose 1075% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.